BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Artificial Life Inc. (ALIF.OB) Announces Opus-M(TM) Health: Dermatitis for Mobile


5/31/2011 9:32:20 AM

LOS ANGELES and HONG KONG, May 31, 2011/PRNewswire-Asia/ --Artificial Life, Inc., (OTC BB: ALIFE), a leading provider of award-winning mobile technology and applications, announced today their upcoming product Opus-M Health: Dermatitis (short form: Opus-M Health: Dt), a healthcare app specifically geared towards the monitoring of the dermatitis skin condition.

Dermatitis is any condition characterized by inflammation of the skin and affects both males and females equally. In the United States, 1 in 30 (or approximately 8 million) people are affected.* While there are various types of dermatitis, all share some common symptoms such as itching, lesions, swelling, and occasional weeping of fluids from the skin. All of these symptoms may be monitored and recorded using Artificial Life (ALIFE)'s Opus-M Health: Dermatitis app.

Opus-M Health: Dermatitis includes a slideshow function for recording pictures of skin conditions and allows for PDF sharing of records via iTunes. Using Opus-M Health: Dermatitis, patients are able to record their skin conditions with more than 10 attribute options such as lesions, distribution, surface texture, and more. In addition, the app contains a body mapping feature to provide a clear and comprehensive indication of affected areas throughout the body. Overall, the Opus-M Health: Dermatitis app allows users to effectively keep track of their dermatitis-related body conditions and easily share this information with their doctors and caregivers.

Features of Opus-M Health: Dermatitis include:

  • Ability to track over 10 core characteristics of inflammation/rashes to provide a more in-depth picture of skin conditions
  • Body mapping feature to show specific areas affected by dermatitis
  • Simple and easy-to-use data input for photo and text recordings
  • A slideshow function to show changes of the condition and healing process over time
  • An interactive graph to track and visualize measurements of areas of the skin being monitored
  • PDF summaries of data that can be exported to patients and caregivers medical records via iTunes sharing
  • Health tips on skin care to minimize the effects of dermatitis

As with all applications in the Opus-M Health family, Opus-M Health: Dermatitis will leverage Artificial Life's Opus-M platform for end-consumers, healthcare providers, and healthcare businesses. The app is scheduled to launch on the Apple App Store in Q2 2011 pending approval and will be available later for Android and Windows Phone 7.

Opus-M Health: Dermatitis follows the Company's successful launch of GluCoMo, its diabetes monitoring app, and Opus-M Health: Neurodermatitis. Artificial Life's Opus-M Health platform will continue to expand and feature more healthcare apps such as the previously announced upcoming apps: Opus-M Health: Neurodermatitis Kids Edition, an expansion of the Opus-M healthcare skin app developed specifically for children affected by neurodermatitis; and Opus-M Health: HIV/AIDS, a healthcare app that is used for the monitoring of HIV/AIDS. More information about apps by Artificial Life can be found at www.botme.com and www.artificial-life.com.

"We are delighted to introduce Opus-M Health: Dermatitis into the Opus-M Health family. With its new features such as the body mapping function, this application shows Artificial Life's constant efforts to enhance the capabilities of its products to better meet the needs of users," said Eberhard Schoneburg, CEO of Artificial Life, Inc.

*Source:
1. "Prevalence and Incidence of Dermatitis," CureResearch.com, May 31, 2011. http://www.cureresearch.com/d/dermatitis/prevalence_printer.htm

App Store is a service mark of Apple Inc.

Android is a trademark of Google Inc. Use of this trademark is subject to Google Permissions.

Windows is a registered trademark of Microsoft Corporation in the United States and/or other countries.

About Artificial Life, Inc.

Artificial Life, Inc. has been a pioneer in artificial intelligence and mobile technology since its inception in Boston in 1994. We are a public US corporation (OTC BB: ALIFE) with listing on the Frankfurt Stock Exchange (Frankfurt: AIF.F; Xetra: AIF.DE) and headquarters and production center in Hong Kong. We have additional offices in Berlin, Germany (EMEA headquarters), Tokyo, Japan, and Santa Monica, USA. Currently our main business areas are: high quality (3D) interactive (massively multiplayer) mobile games, mobile participation television, mobile business applications, our powerful mobile commerce technology platform OPUS-M and our green IT solutions provided by Green Cortex, Inc. We have won many industry awards for our outstanding technology and products.

Facebook: http://www.botme.com/ref/alife-fb
Twitter: http://twitter.com/alifegames
MySpace: http://www.myspace.com/artificial_life_inc
YouTube: http://www.youtube.com/user/alifegames

Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our future results of operations, financial condition and business prospects. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of these terms or other comparable terminology. Although such statements are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on them. These statements involve risks and uncertainties, and actual market trends or our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied in these forward looking statements for a variety of reasons. Potential risks and uncertainties include, but are not limited to, our ability to obtain additional funding to operate and grow our business; the unproven potential of our mobile gaming business model; changing consumer preferences and uncertainty of market acceptance of our products; timely adoption and availability of 3G mobile technology; market acceptance for use of mobile handheld devices to play the interactive games; unpredictable mobile game development schedules; our reliance on a relatively small number of brands; our ability to license brands from others; our dependence upon resellers and telecommunication carriers and operators to distribute our products; our ability to successfully develop, introduce, and sell new or enhanced products in a timely manner; and the timing of new product announcements or introductions by us or by our competitors. For additional discussion of these risks and uncertainties and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB filed on March 16, 2010. We assume no obligation to update any forward-looking statements, which apply only as of the date of this press release.

For more information on ARTIFICIAL LIFE, INC., please contact:

Artificial Life IR and PR Contact:
Adeline Law
Tel: +852-3102-2800
ir@artificial-life.com

SOURCE Artificial Life, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES